Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Pharmacother. 2011 Dec;12(17):2707-12. doi: 10.1517/14656566.2011.630390. Epub 2011 Nov 4.

Mometasone furoate dry powder inhaler for the treatment of asthma.

Author information

  • 1Penn State Hershey Medical Center, Penn State College of Medicine - Pediatrics, Section of Allergy and Immunology, 500 University Drive, Hershey, PA 17033, USA. tfausnight@hmc.psu.edu

Abstract

INTRODUCTION:

Asthma is a chronic inflammatory disease that causes significant morbidity and mortality. Inhaled corticosteroids are the preferred initial treatment for this disorder. Mometasone furoate dry powder is an inhaled corticosteroid that is approved for once-daily treatment of asthma in both adults and children as young as 4 years.

AREAS COVERED:

The goal of this paper is to review the clinical efficacy and safety of mometasone furoate dry powder inhaler for the treatment of asthma. A literature search using PubMed was done using the terms 'mometasone furoate', 'inhaled corticosteroid' and 'asthma', focusing on articles that highlighted clinical trials and addressed efficacy of the medication.

EXPERT OPINION:

Mometasone furoate dry powder inhaler has an excellent safety and efficacy profile. For patients with persistent asthma who require treatment with an inhaled corticosteroid, mometasone furoate is an excellent therapeutic choice.

PMID:
22049912
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk